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Clinical phase I/II studies have demonstrated the safety of gene therapy for a variety of
central nervous system disorders, including Canavan’s, Parkinson’s (PD) and Alzheimer’s
disease (AD), retinal diseases and pain. The majority of gene therapy studies in the CNS
have used adeno-associated viral vectors (AAV) and the first AAV-based therapeutic,
a vector encoding lipoprotein lipase, is now marketed in Europe under the name
Glybera. These remarkable advances may become relevant to translational research
on gene therapy to promote peripheral nervous system (PNS) repair. This short review
first summarizes the results of gene therapy in animal models for peripheral nerve
repair. Secondly, we identify key areas of future research in the domain of PNS-gene
therapy. Finally, a perspective is provided on the path to clinical translation of PNS-
gene therapy for traumatic nerve injuries. In the latter section we discuss the route and
mode of delivery of the vector to human patients, the efficacy and safety of the vector,
and the choice of the patient population for a first possible proof-of-concept clinical
study.
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Gene Therapy in Animal Models for PNS Injury
The peripheral nervous system (PNS) consists of primary sensory neurons in the dorsal
root ganglia and motor neurons in the ventral horn of the spinal cord (Figure 1). Most
peripheral nerves contain axons of sensory and motor neurons and patients who sustain an
injury experience loss of sensory and motor function. In patients regeneration of injured
peripheral axons does occur but is almost never complete. This is due to the low velocity of
axon growth, the deterioration of pro-regenerative Schwann cells in the distal nerve stump
following longer periods of denervation, and the misrouting of regrowing axons (Brushart,
2011; Allodi et al., 2012). Nerve regeneration is studied in well-defined rodent models of
nerve injury. A widely used model is transection of the sciatic nerve of the rat followed by
end-to-end repair of the nerve stumps or implantation of an autograft or artificial nerve
guide to bridge the gap between the stumps. In this model axons reinnervate the end organs
within weeks to months. Cervical or lumbar spinal root avulsions followed by reimplantation
of the roots are much more severe injuries (Eggers et al., 2010; Chu et al., 2012). Following
cervical lesions it can take up to 12 weeks before the first axons reinnervate target cells,
whereas a significant proportion of axons will stall in the nerve and never reach the end
organ. In the lumbar root avulsion model functional recovery is minimal and it is therefore
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FIGURE 1 | Anatomical relationships in the peripheral nervous system
(PNS) and sites of viral vector-mediated gene delivery. The PNS consists
of primary sensory neurons (blue and green: nociceptive and proprioceptive
neurons) in the dorsal root ganglia (DRG) and motor neurons (red) in the ventral
horn of the spinal cord. The axons form a mixed nerve that innervates the skin
and muscle. Successful gene delivery to primary sensory and motor neurons
and to Schwann cells, the resident glia cells of peripheral nerves, has been
reported with various viral vectors. To target primary sensory and motor neurons
two routes of delivery have been used successfully: direct intraganglionic or
intraspinal injection and intrathecal (IT) delivery. Injection of a viral vector in the
nerve stump distal to the lesion or in a nerve graft that bridges the lesion results
in transduction of Schwann cells.
one of the best possible mimics of chronic denervation in human
patients with proximal lesions.
Surgical repair of peripheral nerves has reached its optimal
refinement. Recovery of function as a result of surgical repair
has significantly improved but remains limited. Novel adjuvant
therapeutic strategies to promote axon regeneration in the
injured peripheral nerve are needed to further improve recovery
of function. One of these strategies is gene therapy. Successful
gene delivery to primary sensory and motor neurons and to
Schwann cells, the resident glia cells of peripheral nerves, has
been reported with various viral vectors (Haastert-Talini, 2011;
Mason et al., 2011). Herpes simplex viral vectors attracted early
interest because of their natural tropism for sensory neurons
(Geller and Breakefield, 1988; Glorioso and Fink, 2009). Adeno-
associated viral vectors (AAV) vectors have become popular
as gene delivery agents for neurons of the PNS for several
reasons. AAV have a low risk of insertional mutagenesis and
immunogenicity, they lack endogenous viral genes, can be
produced at high titer and at clinical grade (Salmon et al., 2014;
Felberbaum, 2015; Hastie and Samulski, 2015). There are at least
12 vector serotypes, and a number of AAV variants engineered by
e.g., viral evolution, which display distinct transduction profiles
(Kotterman and Schaffer, 2014). AAV5 is the serotype of choice
for rat sensory neurons (Mason et al., 2010), whereas AAV2, 6,
9 and rh10 efficiently target spinal motor neurons (Peel et al.,
1997; Blits et al., 2004; Snyder et al., 2011; Homs et al., 2014;
Hordeaux et al., 2015). AAV vectors have been used to study the
effects of a variety of genes on regeneration of the central branch
of sensory neurons (Andrews et al., 2009; Bareyre et al., 2011;
Parikh et al., 2011) and on the survival of motor neurons (Blits
et al., 2004; Homs et al., 2014; Pajenda et al., 2014; Hordeaux
et al., 2015).
Schwann cells are central to the success of peripheral nerve
regeneration. However, the unique pro-regenerative properties
of these cells fade away after longer periods of denervation.
Most gene therapy studies used lentiviral vectors to promote the
therapeutic potential of Schwann cells transplanted in artificial
nerve guides or in nerve sheets (Haastert et al., 2006; Li et al.,
2006; Shakhbazau et al., 2012; Godinho et al., 2013; Santosa et al.,
2013) of Schwann cells in autografts (Hoyng et al., 2014a), of
Schwann cells present in damaged nerves distal to an injury
(Tannemaat et al., 2008; Esaki et al., 2011) or in spinal roots
reimplanted in the spinal cord (Eggers et al., 2008). Increased
expression of neurotrophic factors is one of the key events
observed following peripheral nerve injury. Neurotrophic factor
gene therapy stimulated axon regeneration (Mason et al., 2011),
myelination (Haastert et al., 2006, 2008; Homs et al., 2011)
and facilitated the return of compound motor action potentials
(Allodi et al., 2014). Moreover, nerve growth factor (NGF)-
gene therapy was used to promote directional growth of sensory
axons (Hu et al., 2010). Unexpectedly, however, persistent
expression of NGF or glial cell line-derived neurotrophic factor
(GDNF) did cause excessive, modality specific axon growth
and trapping at the site of expression thereby prohibiting distal
growth of axons toward the skin or muscle (Tannemaat et al.,
2008; Santosa et al., 2013; Hoyng et al., 2014a). On the one
hand, these observations highlight the unprecedented potency
of neurotrophic factors. On the other hand they underscore
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the need to control the dose and timing of these therapeutic
proteins. In the next section three key future areas of research
will be discussed, including the optimization of the transduction
of Schwann cells, development of gene switches to control
the timing of transgene expression, and the need to better
understand the biology of the pro-regenerative properties of
Schwann cells.
Key Areas of Future Research
AAV is gaining increasing acceptance as a clinical gene delivery
platform (Hastie and Samulski, 2015). However, in animal
studies PNS-gene therapy to enhance the performance of
Schwann cells largely relied on lentiviral vector or adenoviral
vector-mediated gene delivery (Mason et al., 2011), with the
exception of one recent study that used AAV (Homs et al.,
2011). Lentiviral vectors integrate their genetic information
into the host cell genome, whereas transgene expression via
adenoviral vectors rapidly declines as a result of immune-
mediated toxicity (Hermens and Verhaagen, 1997; Dijkhuizen
et al., 1998). Although the overall risk of lentiviral vector-
associated insertional mutagenesis is low (De Palma et al.,
2005; Montini et al., 2006), lentiviral vectors could potentially
be harmful for the transduced cells. Surprisingly, very little
information is available on the transduction of Schwann cells
with AAV vectors (Homs et al., 2011). A recent comparative
study of nine AAV serotypes and lentiviral vectors shows
that optimal transduction of rat and human Schwann cells
is achieved by different serotypes. Rat nerve segments could
be genetically modified equally well by a set of four AAV
vectors (AAV1, 5, 7, 9), whereas AAV2 was superior in human
nerve segments (Hoyng et al., 2015; Figure 2). Transduction
with lentiviral vectors was, however, superior to the best AAV
vectors. Thus, a first key area of future research would be
to further optimize gene delivery to Schwann cells, either by
identifying newly engineered AAV vectors with an improved
tropism for Schwann cells (Kotterman and Schaffer, 2014), or
by testing lentiviral vectors with an improved safety profile,
e.g., non-integrating lentiviral vectors (Yáñez-Muñoz et al.,
2006; Cesana et al., 2014). In vivo electroporation of expression
plasmids in Schwann cells could be an alternative to viral vector-
directed gene delivery (Aspalter et al., 2009; Pereira Lopes et al.,
2013). Plasmid-mediated gene transfer is a straight forward
procedure, however, the strong electrical currents required
for the electroporation, the relatively low transduction rate,
and short-lived expression of the therapeutic gene indicate
that in vivo plasmid-based gene transfer will have limited
utility.
A second area of key future research concerns the creation
of a safe regulatable gene therapy vector. In the context
of PNS-gene therapy this is essential for two reasons. First,
persistent expression of certain growth factors leads to local
trapping of axons (discussed above). Second, continued growth
factor expression may have unacceptable side-effects, e.g., Nerve
growth factor (NGF) may induce hypersensitivity (Verge et al.,
2014). The criteria for regulated vector-based therapeutic gene
expression are that: (1) it can be induced by a small molecule
FIGURE 2 | AAV2-mediated transduction of a human sural nerve
segment. Surplus human nerve material was obtained from the operation
room and anonymized as stated in the code of conduct for responsible use of
human tissue and medical research (Federa, 2011). Nine AAV serotypes were
compared for their transduction efficiency by injecting 1.85 × 1010 gc/cm
nerve and culturing the nerve segments for 14 days. After 14 days nerve
segments were immersion fixed with paraformaldehyde and 20 µm sections
were prepared. The upper panel show a section through a human sural nerve
stained for GFP. The middle panel shows the same image stained for the
nuclear stain Hoechst and the lower panel shows the merged images of the
two panels. AAV2 transduced numerous cells that display the typical
longitudinal shape of Schwann cells and this serotype was superior to all other
serotypes tested. More details on this study can be found in Hoyng et al.
(2015).
that is safe; (2) it can be turned off effectively by withdrawal
of the inducer whereas ‘‘leaky’’ expression should be minimal
and preferably undetectable; and (3) the transactivator protein
(TA) that is employed should be non-immunogenic and well-
tolerated. The prototypical system for regulating gene expression
involves a TA that binds to a promoter in the presence of
doxycycline. However, the TA is a bacterial protein and is
therefore a permanent immunological target (Markusic and
Seppen, 2010). Clinical use of analogous systems using alternative
TAs is precluded for the same reason. Viruses have evolved
several strategies to escape immune surveillance (Zaldumbide
and Hoeben, 2008). We took advantage of the long Gly-
Ala repeat (GAr) domain of Epstein Barr virus (Yin et al.,
2003) to generate an immunologically inert version of the TA.
This idea was based on the observation that Schwann cells
which express a foreign protein (e.g., green fluorescent protein,
GFP) are cleared from the nerve by an immune response.
This does not happen when these proteins are fused to GAr
(Ossevoort et al., 2006; Hendriks et al., 2007). We fused GAr
to TA and showed that GAr-TA retains its sensitivity to
doxorubicin (dox). This system has been used to turn GDNF
expression ‘‘on’’ and ‘‘off’’ in rat sciatic nerve. The GAr-
TA system is several fold less ‘‘leaky’’ compared to the TA
protein. GAr-TA displays strongly reduced immunogenicity in
a bioassay for antigenic peptide generation. Therefore, the GAr-
TA system fulfills many of the criteria for safe regulatable gene
expression (Hoyng et al., 2014b). However, GAr-TA requires
doxycycline concentrations that are 40-fold higher than clinically
acceptable levels. Therefore, current studies focus on testing
newer versions of the TA (Das et al., 2008) and shorter
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GAr tags which may have improved doxycycline sensitivity.
Another complication that may occur is that the continuous
presence of the immune-inert TA in cells may induce unwanted
effects. Therefore efforts are ongoing to regulate therapeutic
and TA gene expression simultaneously. Apart from ligand
(i.e., doxcycyline) regulated promoters, promoters induced by
physiological stimuli associated with neural injury may emerge
as tools to restrict transgene expression to the post-lesion period
(Jazwa et al., 2013). The glia fibrillary acidic protein (GFAP)-
promoter is an example of an injury induced promotor that
has been used in transgenic mice to turn on gene expression
in a diseased peripheral nerve (Keller et al., 2009). However
GFAP continues to be expressed in non-myelinating Schwann
cells in an intact nerve which would result in some level of
persistent transgene expression after nerve regeneration has been
completed.
Optimization of gene delivery to Schwann cells and
the creation of safe regulatable gene therapy vectors are
biotechnological challenges. A third area of future research
concerns the gathering of fundamental biological know-how
on the cellular and molecular properties of Schwann cells in
a regenerating nerve. A nerve injury induces major, tightly
coordinated changes in gene expression in Schwann cells
in the distal nerve. Together with the typical alignment of
Schwann cells in pathways for growing axons, this creates a
unique environment for successful regeneration. The signals that
transform stable Schwann cells into the specialized repair cells
in an injured nerve are not clearly understood and it is not
known why Schwann cells gradually lose their pro-regenerative
properties after longer times of denervation (Gordon et al.,
2011). Moreover, growing evidence indicates the existence of
Schwann cells with distinct phenotypes preferentially supporting
either motor or sensory neuron regeneration (Wright et al.,
2014) which is relevant to direct growing axons to their correct
target cells.
To develop new strategies to stimulate axon regeneration, an
analysis of the mechanisms that underlie the pro-regenerative
properties of Schwann cells is needed. Conditional knock-out
of the gene for the transcription factor c-Jun in Schwann
cells has a negative impact on axon regeneration and results
in simultaneous down-regulation of multiple pro-regenerative
proteins in Schwann cells in an injured nerve (Arthur-Farraj
et al., 2012). Neurotrophic factor expression in Schwann cells
can be enhanced by overexpression of c-Jun (Huang et al.,
2015). C-Jun appears to be one, of perhaps a small set, of
central transcriptional ‘‘master switches’’ which, in a cooperative
manner, control the pro-regenerative phenotype of Schwann
cells (Hung et al., 2015). If, in future experiments, the key
regulatory complex of transcription factors are identified,
these genes would be prime targets for Schwann cell gene
therapy. ‘‘Transcriptional reprogramming’’ of Schwann cells
is fundamentally different from PNS-gene therapy with a
vector encoding a single neurotrophic factor because this
would result in an elaborate repertoire of molecular changes
(Huang et al., 2015), which would be particularly beneficial
during the intermediate and later phases of the regeneration
process when the ability of Schwann cells to support axonal
outgrowth deteriorates (Gordon et al., 2011). The identification
of the transcriptional ‘‘master switches’’ and studies on their
combinatorial role in determining the repair-properties of
Schwann cells may also shed new light on the occurrence of
specific ‘‘motor’’ and ‘‘sensory’’ specific Schwann cells (Wright
et al., 2014).
Path to a Clinical Study
The preclinical issues discussed above require several more
years of systematic research in rodents. A clinical study to
promote PNS regeneration by gene therapy is therefore currently
hypothetical. However, the rapidly growing clinical experience
with gene therapy for other neurological diseases and the steady
advances in preclinical PNS-gene therapy support the conception
of a framework for a future clinical study. The development of a
PNS-gene therapy study will benefit particularly from experience
with gene therapy for pain and neuromuscular diseases. In these
disorders the sensory (pain) and motor neurons and muscle cells
(neuromuscular disorders) are the primary target cells (Pleticha
et al., 2014a; Cheever et al., 2015). Gene therapy for traumatic
nerve injury has to include methods for safe gene transfer to
the nerve Schwann cells as well. The following three topics
need careful consideration in the context of preclinical-to-clinical
translation of PNS-gene therapy and will be discussed below:
(1) the route and mode of delivery of the vector; (2) the efficacy
and safety of the vector; and (3) the choice of the patient
population.
Route and Mode of Delivery of the Vector
Pleticha and colleagues presented a roadmap for the preclinical
evaluation of AAV-based genetic modification of dorsal root
ganglia (DRG) for clinical trials on pain (Pleticha et al., 2014a).
This roadmap covers the essential preclinical steps needed
to realize safe AAV-mediated targeting of primary sensory
neurons in human patients. The human DRG is approximately
50 times larger than the rat DRG (Shen et al., 2006). The
rat motor neuron pool that supplies the nerves that innervate
the forepaw (equivalent to the brachial plexus in humans)
spreads over 0.5 cm of cervical cord, whereas the motor
neuron pool innervating the brachial plexus in humans spans
at least 10 cm of the spinal cord. The longest rat peripheral
nerve, the sciatic nerve, is approximately 12 cm long while
the nerves that innervate the human arm measure 80–100 cm.
Therefore, translating gene therapy to the PNS of humans
poses specific challenges with respect to the route and mode
of delivery of the vector because of the diverging anatomical
dimensions of the rodent and human PNS (Pleticha et al.,
2014a).
To target primary sensory and motor neurons two routes
of delivery have successfully been used: direct intraganglionic
or intraspinal injection and intrathecal (IT) delivery. In the
rat a single intraganglionic injection of an AAV vector
results in efficient transduction of sensory neurons with
very little if any spread of the vector to other locations
(Mason et al., 2010). In contrast, IT delivery results in
transduction of sensory and spinal motor neurons and other
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non-neuronal cell types (Snyder et al., 2011). In humans,
lumbar puncture is a relatively safe and standard technique to
approach the cerebrospinal fluid and it would be feasible to
deliver a vector to human DRGs and spinal motor neurons
via this route. AAV vectors were delivered to the cat, the
pig and to non-human primates using a lumbar puncture
technique (Bucher et al., 2013; Gray et al., 2013; Pleticha
et al., 2013; Samaranch et al., 2013; Dirren et al., 2014;
Passini et al., 2014). If expression of a transgene in areas
outside the DRG is not desirable, direct injection would be
a requirement. Convection enhanced delivery (CED) relies
on enhanced extracellular transport of a solution infused in
tissue over an extended period of time (typically ranging
from 20 min to 2 h, Krauze et al., 2005a,b) and results in
equal tissue distribution of the infusate. Minimally invasive
intra-ganglionic gene transfer by CT-guided percutaneous
injection and CED of AAV1 in lumbar DRGs of the pig
resulted in 33% transduction of DRG neurons (Pleticha et al.,
2014c).
Gene transfer to the injury-repair site of a human peripheral
nerve will require a method to deliver a vector to a sural nerve
graft inserted to connect the proximal and distal stump or to
the nerve distal to the repair site. In rats, when relying on
diffusion of the viral vector during a single manually guided
1–2 µl injection, the vector spreads in a nerve graft or in
a nerve stump distal to a repair site over several millimeters
(Tannemaat et al., 2008; Hoyng et al., 2014a). Four injections
placed at 5–8 mm distances from each other resulted in
the transduction of a 4–5 cm long segment of rat sciatic
nerve (Eggers et al., 2013). This injection technique results
in rather unequal transduction of Schwann cells, with ‘‘hot
spots’’ containing many transduced cells, and areas with no
or very little transduced cells. CED carries macromolecules
(such as Gadolinium-labeled Albumine for direct monitoring
of the infusion process) over a distance of 1 cm in a rat
nerve (Pleticha et al., 2014b) and over distances of 2.7–3.5 cm
in a nerve of a non-human primate (Ratliff and Oldfield,
2001; Chen et al., 2011). Importantly, and in contrast to
manual injection of small volumes of vector solution, CED
resulted in an equal distribution of the infusate over the
nerve. Future studies have to test whether CED of a viral
vector to an injured nerve of a larger animal is a feasible
option. Taken together, gene therapy for traumatic nerve injuries
will benefit significantly from the encouraging observations
in larger animals which show that the neuroanatomical
dimensions do not preclude efficient gene delivery to the
human PNS.
Safety and Efficacy of the Vector
Rigorous toxicity, and serological and cellular immune
assessments have been performed for AAV1, AAV2, AAV5
AAV8 and AAVrh10. These serotypes have been used in
clinical trials for lipoprotein lipase deficiency (LPLD; AAV-1;
Scott, 2015), Canavan disease, PD and AD (AAV-2; Leone
et al., 2000, 2012; Kaplitt et al., 2007; Richardson et al., 2011;
Bartus et al., 2013; Rafii et al., 2014), liver mediated diseases
(AAV5; Grosios and Pañeda, 2013), San Fillipo B (AAV5,
AAVrh10; Tardieu et al., 2014)1 and Hemeophilia B (AAV-5,
AAV-8; Nathwani et al., 2014). Although most humans have
natural occurring neutralizing antibodies against AAV and
treatment with AAV usually results in enhanced levels of
these antibodies, this occurred without detectable pathological
effects (Salmon et al., 2014). Screening of patients following
application of an AAV-1 vector to skeletal muscle resulted in
seropositivity for AAV1 (Ferreira et al., 2014; Salmon et al.,
2014). Antibodies which develop after the administration
of AAV1 would not interfere with the therapeutic effect as
the AAV vector has already delivered its therapeutic cargo.
However, preexisting antibodies may interfere significantly
with the transduction process as has been shown in some
studies (Samaranch et al., 2013), whereas neutralizing
antibodies had no effect on gene delivery with AAV after
intraparenchymal or IT injection in other studies (Gray et al.,
2013).
Transduction differences between different serotypes in
rat, larger animals and human complicates the choice of
the vector for preclinical-to-clinical translation. The use of
primary human tissue, either biopsy material or autopsy
tissue, may prove to be critical in determining the optimal
serotype for human patients. In our hands, cultured human
peripheral nerve segments, obtained as left-over tissue
from the operation theater after nerve repair surgery, were
transducible by lentiviral vectors (Tannemaat et al., 2007),
whereas AAV-serotype testing showed that AAV2 was superior
to eight other common serotypes investigated (Hoyng et al.,
2015; Figure 2). To date, AAV2 has been used in several
clinical trials and, together with AAV1, is one of the best
characterized serotypes. AAV2 outperforms other serotypes
in human nerve segments and is therefore currently the
leading vector for a clinical study that aims at enhancing the
therapeutic potential of Schwann cells in a human peripheral
nerve.
The Choice of the Patient Population
Animal models will provide information about the efficacy and
safety of the delivery technique, the vector and the transgene.
However, the predictive value of animal studies is limited and
eventually a study on a small number of human subjects with
a PNS-lesion will be a necessary step in the translation process
(Cheever et al., 2015). An early gene therapy study for AD
enrolled eight patients (Tuszynski et al., 2005). This study was
too small to demonstrate efficacy, but showed that the gene
therapy procedure was feasible and well-tolerated. The transgene
was NGF, a growth factor relevant in the context of PNS-gene
therapy. NGF expression was detectable in post-mortem brain
tissue of a subject that died of causes unrelated to the gene
delivery procedure. This shows that a small clinical study can be
highly informative andmay form the basis of a larger randomized
gene therapy trial (Cheever et al., 2015).
Nerve injury is a heterogeneous condition, ranging from
brachial plexus injuries to distal injuries of the digital
1http://www.uniqure.com/news/182/182/Clinical-trial-launched-to-treat-
Sanfilippo-B-syndrome-using-gene-therapy.html
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nerves that innervate the hand. Established guidelines on
the design of clinical trials for the evaluation of novel
treatments for nerve injury do not (yet) exist. Previous
trials to test experimental treatments to promote nerve
regeneration involved patients that sustained very different
types of injuries. A recent successful clinical trial on the
beneficial effect of electrical stimulation was performed on
patients with complete transection injury of the digital nerve
(Wong et al., 2015). An advantage of this study population
is its relative homogeneity. Although a clinically meaningful
degree of regeneration occurs spontaneously in these patients,
enhanced sensory reinnervation was detectable following a
short period of per-operative electrical stimulation. A follow-
up trial with electrical stimulation as adjuvant treatment
to surgical repair in patients with a severe brachial plexus
injury, a severe lesion that causes serious dysfunction of
the arm with prospects of only limited functional recovery
of biceps function, is currently underway.2 Thus, although
electrical stimulation is a straight-forward procedure shown
to be effective and safe in animals (Al-Majed et al., 2000;
Brushart et al., 2005; Gordon et al., 2008, 2010; Haastert-
Talini et al., 2011), tolerability and efficacy were first studied
in a patient population that sustained a lesion with relatively
moderate medical consequences before translating the procedure
to lesions associated with long-lasting disability. A similarly
cautious and phased translational path for PNS-gene therapy is
mandatory.
2www.clinicaltrials.gov
Gene therapy for neurotrophic factors was well-tolerated
in Alzheimer’s (NGF; Rafii et al., 2014) and Parkinson’s
disease (Neurturin; Bartus et al., 2013) patients. In contrast to
neurotrophic factor gene therapy in the brain, neurotrophic
factor gene delivery to an injured peripheral nerve is not
without risk, as it may induce uncontrolled growth of axons,
hypersensitivity and unwanted changes in Schwann cells (Mason
et al., 2011). As discussed above, animal studiesmust first provide
robust experimental evidence showing that control over the
dose and the timing of viral vector-derived neurotrophic factor
expression is effective, before gene therapy in a small group of
patients with a nerve lesion can be undertaken. A gene therapy
study in patients with a digital nerve injury, as performed for
electrical stimulation, may reveal potential unwanted effects, and
monitoring benefit is possible with the current battery of sensory
tests (Wong et al., 2015). The vector, preferably an immune-
inert regulatable AAV vector encoding NGF (a growth factor
with stimulatory effects on sensory fibers) would be delivered to
the denervated digital nerve by CED or by multiple injections
along the 6–10 cm long digital nerve immediately following
end-to-end repair. While this pilot study could be important
in demonstrating safety and tolerability of PNS gene therapy,
the therapeutic benefit of gene therapy for digital nerve injury
patients is probably limited as this nerve displays a significant
degree of spontaneous regeneration. Patients with a brachial
plexus injury, a lesion which has a permanent negative impact,
are a target group where gene therapeutic intervention could
develop into a genuine adjuvant regenerative treatment strategy
to further promote repair after neurosurgical intervention.
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